APG808, an anti-IL-4R? monoclonal antibody, demonstrates safety, extended half-life, and sustained inhibition of type 2 inflammatory biomarkers - Amsterdam 2025

Biologics for asthma and allergic rhinitis: novel trial data

Chair(s): Alberto Papi, Ran Wang

Session type: Poster session

APG808, an anti-IL-4R? monoclonal antibody, demonstrates safety, extended half-life, and sustained inhibition of type 2 inflammatory biomarkers

Amol Kamboj

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

A Multinational Phase 2, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effect of Linvemastat (MMP12 inhibitor) in Patients with Uncontrolled Asthma on Inhaled Corticosteroids (ICS) with Long-Acting Beta Agonist (LABA) as SOC

Bassem Elmankabadi

Poster

Abstract

Rapid and sustained FEV1 improvements with rademikibart in type 2 asthma: Impact of eosinophils and FENO

Raul Collazo

Poster

Abstract

Clinical remission in patients with asthma treated with twice-yearly depemokimab in the Phase III SWIFT-1/2 studies

Michael E. Wechsler

Poster

Abstract

Twice-yearly depemokimab demonstrates sustained pharmacokinetics and pharmacodynamics across Phase I and III trials

Stein Schalkwijk

Poster

Abstract

Geographic variation in outcomes in RCTs of biologic therapies in patients with asthma or COPD: A systematic literature review

David J. Jackson

Poster

Abstract

Twice-yearly depemokimab reduces exacerbations versus placebo in patients with asthma across age of onset/duration subgroups: Phase III SWIFT-1/2 studies

David J. Jackson

Poster

Abstract

Twice-yearly depemokimab demonstrates efficacy in patients with asthma across baseline medium- and high-dose ICS subgroups: Phase III SWIFT-1/2 studies

Ian D. Pavord

Poster

Abstract

Dose Optimization and Exposure-Response Analyses to Support the Dose Selection of TQC2731, a Novel Anti-TSLP Monoclonal Antibody, in Patients with Severe Asthma

Li Mei

Poster

Abstract

A Phase 1 randomized, double-blind study of safety, tolerability and pharmacokinetics of Solrikitug in healthy participants

Bojan Lalovic

Poster

Abstract

Rademikibart in moderate-to-severe asthma: Impact of eosinophils and regional differences on response

Raul Collazo

Poster

Abstract

Bronchoscopy measurements of tezepelumab pharmacokinetics and TSLP in asthmatic patients

Jacob Leander

Poster

Abstract

Predicting long-term remission with benralizumab in severe eosinophilic asthma (SEA): Post-hoc analysis of SIROCCO, CALIMA, BORA

David Price

Poster

Abstract

Relationship between early lung function improvement with dupilumab and long-term clinical improvement in chronic obstructive pulmonary disease

Frits M.e. Franssen

Poster

Abstract

Evaluation of ACQ-5 components from the rilzabrutinib phase 2 asthma study

Jorge Fernando Maspero

Poster

Abstract

First-in-human study of 9MW1911 (an anti-ST2 monoclonal antibody) in healthy volunteers

Danfeng Yin

Poster

Abstract

A study to investigate the safety, tolerability and pharmacokinetics of londamocitinib, an inhaled Janus kinase 1 inhibitor, in healthy Japanese and Chinese participants (NCT06519968)

Mohd Nubli Mustapa

Poster

Abstract

OCS reduction with tezepelumab in OCS-dependent patients with severe allergic, eosinophilic asthma in WAYFINDER

Guy Brusselle

Poster

Abstract

Absorption, distribution, metabolism, and elimination (ADME) study strengthens clinical pharmacology package of londamocitinib

Julia Lund

Poster

Abstract

APG808, an anti-IL-4R? monoclonal antibody, demonstrates safety, extended half-life, and sustained inhibition of type 2 inflammatory biomarkers

Amol Kamboj

Poster

Abstract

Twice-yearly depemokimab is well-tolerated in randomised, double-blind, placebo-controlled Phase III SWIFT and ANCHOR studies

Marjolein Cornet

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}